Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Vect-Horus logo — Enhancing the transport of therapeutic and imaging agents us...

Vect-Horus

Enhancing the transport of therapeutic and imaging agents using versatile and flexible targeting technologies

Founded 2005 France France 51 employees Series D Total: $18.00M Biopharma, Biotechnology +2

General Information

Company Name Vect-Horus
Founded Year 2005
Location France France
Founders / Decision Makers
Team member
Employees 51
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with Vect-Horus. To contact Vect-Horus, visit vect-horus.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Vect-Horus compare?

A PDF of Vect-Horus and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Vect-Horus soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Vect-Horus

Vect-Horus is a French biotechnology startup founded in 2005, specializing in enhancing the transport of therapeutic and imaging agents using versatile and flexible targeting technologies. The company's innovative vectors aim to facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumors. One of its key achievements is overcoming natural barriers, particularly the blood-brain barrier, allowing access for these agents to their targets. With a strong foundation in academic collaborations with CNRS, INSERM, and CEA, Vect-Horus has also ventured into industrial partnerships. Its pioneering VECTrans® technology serves as the cornerstone of a mixed business model, offering its platform to pharmaceutical and biotechnology company partners and developing an internal pipeline of products. The company secured a noteworthy €5.30M Series D - VECT investment in December 2020. With a dedicated team of 35 employees primarily focused on R&D, Vect-Horus continues to showcase its potential in the biopharma, biotechnology, healthcare, and life sciences industries.

Business keywords: Drug delivery technology, Biotechnology research, Targeted drug delivery, Neurological therapeutics, Receptor-mediated transport, Peptide-based vectors, Biological barrier crossing technology

Services & Products

Developing and Enhancing Targeting Technology for Therapeutic and Imaging Agents Transport

Target Customers

Biopharmaceutical Companies Healthcare Institutions Research Institutions

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series D Vect €5.30M -
01 Dec 2020
Series D Vect €6.70M -
09 Sep 2020
Venture Round Vect €3.50M 3
SCR Provençale et Corse, Financière Tuileries Co-Invest +1
07 Jun 2018
Venture Round Vect €2.50M -
06 Jun 2017
Non Equity Assistance Vect Undisclosed 1
Incubateur Impulse
Incubateur Impulse
14 May 2001

Vect-Horus Alternatives & Competitors

View All Alternatives
Vect-Horus vs
Alcyone Lifesciences
Alcyone Lifesciences

Empowering Precision Therapies for Rare Neurological Disorders

Venture round
Biotechnology, Health Care
Compare Vect-Horus vs Alcyone Lifesciences
Vect-Horus vs
Travecta Therapeutics
Travecta Therapeutics

Pioneering advancements in central nervous system treatments with innovative solutions for crossing...

Series A
Biotechnology, Health Care
Compare Vect-Horus vs Travecta Therapeutics
Vect-Horus vs
Arrogene, Inc.
Arrogene, Inc.

Innovative cancer treatment technology delivering advanced nano agents to target tumors, enhancing p...

Venture round
1 employees
Biotechnology, Health Care
View all alternatives

FAQ About Vect-Horus

Enhancing the transport of therapeutic and imaging agents using versatile and flexible targeting technologies
Vect-Horus was founded in 2005.
Vect-Horus is headquartered in France.
Vect-Horus operates in Biopharma, Biotechnology, Health Care and Life Sciences. Its work centres on Drug delivery technology, Biotechnology research, Targeted drug delivery and Neurological therapeutics. Its customers include Biopharmaceutical Companies, Healthcare Institutions and Research Institutions.
Vect-Horus has approximately 51 employees.
Vect-Horus has completed 5 funding rounds, raising a total of $18.00M. The latest funding stage is Series D.
Vect-Horus offers: Developing and Enhancing Targeting Technology for Therapeutic and Imaging Agents Transport.
Top alternatives and competitors to Vect-Horus include Alcyone Lifesciences, Travecta Therapeutics, Arrogene, Inc., ViaNautis, Nuage Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vect-Horus and Alcyone Lifesciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Vect-Horus, https://bouncewatch.com/company/vect-horus, updated 7 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes